GENETIC POLYMORPHISMS OF HEMOSTATIC FACTORS AND THROMBOTIC RISK IN NON BCR-ABL MYELOPROLIFERATIVE NEOPLASMS: A PILOT STUDY
Dambrauskienė R1,*, Gerbutavičius R1, Ugenskienė R2, Jankauskaitė R2, Savukaitytė A2, Šimoliūnienė R3, Rudžianskienė M1, Gerbutavičienė R4, Juozaitytė E1
*Corresponding Author: Rūta Dambrauskienė, Department of Oncology and Hematology, Institute of Oncology, Lithuanian University of Health Sciences, Eivenių str. 2, LT-50009 Kaunas, Lithuania. Tel.: +370-3732-6303. Fax: +370-3732-6413. E-mail: ruta.dambrauskiene@gmail.com
page: 35

REFERENCES

1. Polycythemia vera: The natural history of 1213 patients followed for 20 years. Gruppo italiano studio policitemia. Ann Intern Med. 1995; 123(9): 656-664. 2. Cortelazzo S, Viero P, Finazzi G, D’Emilio A, Rodeghiero F, Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol. 1990; 8(3): 556-562. 3. Barbui T, Carobbio A, Cervantes F, Vannucchi AM, Glglielmelli P, Antonioli E, et al.Thrombosis in primary myelofibrosis: Incidence and risk factors. Blood. 2010; 115(4): 778-782. 4. Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzoni P, Valentini M, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med. 2004; 117(10): 755-761. 5. Watson KV, Key N. Vascular complications of essential thrombocythaemia: A link to cardiovascular risk factors. Br J Haematol. 1993; 83(2): 198-203. 6. Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: An international study. J Clin. Oncol. 2011; 29(23): 3179-3184. 7. Enblom A, Lindskog E, Hasselbalch H, Hersby D, Bak M, Tetu J, et al. High rate of abnormal blood values and vascular complications before diagnosis of myelopro-liferative neoplasms. Eur J Intern Med. 2015; 26(5): 344-347. 8. Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, et al. Somatic mutations of cal-reticulin in myeloproliferative neoplasms. N Engl J Med. 2013; 369(25): 2379-2390. 9. Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013; 369(25): 2391-2405. 10. Fleischman AG, Tyner JW. Causal role for JAK2 V617F in thrombosis. Blood. 2013; 122(23): 3705-3706. 11. Tefferi A, Thiele J, Vannucchi AM, Barbui T. An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms. Leukemia. 2014; 28(7): 1407-1413. 12. Peerschke EIB, Lopez JA. Platelet membranes and receptors. In: Loscalzo J, Schafer AI, Eds. Thrombosis and Hemorrhage, 2nd ed. Baltimore, MD, USA: Williams and Wilkins. 1998: 229-260. 13. Andrews RK, Shen Y, Gardiner EE, Dong JF, Lopez JA, Berndt MC. The glycoprotein ib-IX-V complex in platelet adhesion and signaling. Thromb Haemost. 1999; 82(2): 357-364. 14. Ruggeri ZM. Platelets in atherothrombosis. Nat Med. 2002; 8(11): 1227-1234. 15. Ruggeri ZM. New insights into the mechanisms of platelet adhesion and aggregation. Semin Hematol. 1994; 31(3): 229-239. 16. Afshar-Kharghan V, Lopez JA, Gray LA, Padilla A, Borthakur G, Roberts SC, et al. Hemostatic gene poly-morphisms and the prevalence of thrombotic complications in polycythemia vera and essential thrombocythemia. Blood Coagul Fibrinolysis. 2004; 15(1): 21-24. 17. Hoffman M, Colina CM, McDonald AG, Arepally GM, Pedersen L, Monroe DM. Tissue factor around dermal vessels has bound factor VII in the absence of injury. J Thromb Haemost. 2007; 5(7): 1403-1408. 18. Buxhofer-Ausch V, Olcaydu D, Gisslinger B, Schalling M, Frantal S, Thiele J, et al. Decanucleotide insertion polymorphism of F7 significantly influences the risk of thrombosis in patients with essential thrombocythemia. Eur J Haematol. 2014; 93(2): 103-111.19. Bowen DJ, Collins PW. An amino acid polymorphism in von willebrand factor correlates with increased susceptibility to proteolysis by ADAMTS13. Blood. 2004; 103(3): 941-947. 20. van ’t Hooft FM, Silveira A, Tornvall P, Iliadou A, Ehrenborg E, Eriksson P, et al. Two common functional polymorphisms in the promoter region of the coagulation factor VII gene determining plasma factor VII activity and mass concentration. Blood. 1999; 93(10): 3432-3441. 21. Croft SA, Samani NJ, Teare MD, Hampton KK, Steeds RP, Channer KS, et al. Novel platelet membrane glycoprotein VI dimorphism is a risk factor for myocardial infarction. Circulation. 2001; 104(13): 1459-1463. 22. Pina-Cabral LB, Carvalhais V, Mesquita B, Escór-cio C, Salgado P, Santos A, et al. Allelic and genotypic frequencies of platelet glycoprotein polymorphisms in a portuguese population. Rev Port Cardiol. 2013; 32(2): 111-115. 23. Jimenez S, Tassies D, Espinosa G, Garcķa-Criado A, Plaza J, Monteagudo J, et al. Double heterozygosity polymorphisms for platelet glycoproteins Ia/IIa and IIb/ IIIa increases arterial thrombosis and arteriosclerosis in patients with the antiphospholipid syndrome or with systemic lupus erythematosus. Ann Rheum Dis. 2008; 67(6): 835-840. 24. Yonal I, Hindilerden F, Hancer VS, Artim-Esen B, Daglar A, Akadam B, et al. The impact of platelet membrane glycoprotein ib alpha and Ia/IIa polymorphisms on the risk of thrombosis in the antiphospholipid syndrome. Thromb Res. 2012; 129(4): 486-491. 25. Ye Z, Liu EH, Higgins JP, Keavney BD, Lowe GD, Collins R, et al. Seven haemostatic gene polymorphisms in coronary disease: Meta-analysis of 66,155 cases and 91,307 controls. Lancet. 2006; 367(9511): 651-658. 26. Hoppe B, Tolou F, Dorner T, Kiesewetter H, Salama A. Gene polymorphisms implicated in influencing susceptibility to venous and arterial thromboembolism: Frequency distribution in a healthy german population. Thromb Haemost. 2006; 96(4): 465-470. 27. Zhang LJ, Li HH, Tao SB, Yuan B, Yan HQ, Chang L, et al. FGB gene - 148C>T polymorphism is associated with increased risk of ischemic stroke in a Chinese population: A meta-analysis based on 18 case-control studies. Genet Test Mol Biomarkers. 2014; 18(6): 377-382. 28. Zhang X, Li Y, Guo X, Du L, Ma J. Relationship between the -455G/A and -148C/T polymorphisms in the β-fibrinogen gene and cerebral infarction in the Xinjiang Uygur and Han Chinese populations. Neural Regen Res. 2012; 7(7): 546-551. 29. Liang L, Sun C, Xiao F, Tang XL, Chen XD, Zhou DF, et al. (See above) Nine polymorphisms of fibrinogen gene and their association with plasma fibrinogen levels in Hainan Han population. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2005; 22(4): 457-461.PAGE 30. Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: An international study of 891 patients. Blood. 2011; 117(22): 5857-5859. 31. Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, et al. Development and validation of an international prognostic score of thrombosis in world health organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012; 120(26): 51825133. 32. Dahlback B, Hildebrand B. Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc Natl Acad Sci USA. 1994; 91(4): 1396-1400. 33. Ruggeri M, Gisslinger H, Tosetto A, Rintelen C, Mannhalter C, Pabinger I, et al. Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia. Am J Hematol. 2002; 71(1): 1-6. 34. Schwarz J, Ovesná P, Černá O, Kissová J, Maaloufová Soukupová J, Brychtová Y, et al.; CZEMP-Czech Group for Ph- Myeloproliferative Disorders. Thrombosis in thrombocythemic Ph- myeloproliferations is associated with higher platelet count prior to the event: results of analyses of prothrombotic risk factors from a registry of patients treated with anagrelide. Eur J Haematol. 2016; 96(1): 98-106. 35. De Stefano V, Za T, Rossi E, Fiorini A, Ciminello A, Luzzi C, et al. Influence of the JAK2 V617F mutation and inherited thrombophilia on the thrombotic risk among patients with essential thrombocythemia. Haematologica. 2009; 94(5): 733-737. 36. Tevet M, Ionescu R, Dragan C, Lupu AR. Influence of the JAK2 V617F Mutation and inherited thrombophilia on the thrombotic risk among patients with myelo-roliferative disorders. Maedica (Buchar). 2015; 10(1): 27-32.



Number 26
Number 26 VOL. 26(2), 2023 All in one
Number 26
VOL. 26(2), 2023
Number 26
VOL. 26, 2023 Supplement
Number 26
VOL. 26(1), 2023
Number 25
VOL. 25(2), 2022
Number 25
VOL. 25 (1), 2022
Number 24
VOL. 24(2), 2021
Number 24
VOL. 24(1), 2021
Number 23
VOL. 23(2), 2020
Number 22
VOL. 22(2), 2019
Number 22
VOL. 22(1), 2019
Number 22
VOL. 22, 2019 Supplement
Number 21
VOL. 21(2), 2018
Number 21
VOL. 21 (1), 2018
Number 21
VOL. 21, 2018 Supplement
Number 20
VOL. 20 (2), 2017
Number 20
VOL. 20 (1), 2017
Number 19
VOL. 19 (2), 2016
Number 19
VOL. 19 (1), 2016
Number 18
VOL. 18 (2), 2015
Number 18
VOL. 18 (1), 2015
Number 17
VOL. 17 (2), 2014
Number 17
VOL. 17 (1), 2014
Number 16
VOL. 16 (2), 2013
Number 16
VOL. 16 (1), 2013
Number 15
VOL. 15 (2), 2012
Number 15
VOL. 15, 2012 Supplement
Number 15
Vol. 15 (1), 2012
Number 14
14 - Vol. 14 (2), 2011
Number 14
The 9th Balkan Congress of Medical Genetics
Number 14
14 - Vol. 14 (1), 2011
Number 13
Vol. 13 (2), 2010
Number 13
Vol.13 (1), 2010
Number 12
Vol.12 (2), 2009
Number 12
Vol.12 (1), 2009
Number 11
Vol.11 (2),2008
Number 11
Vol.11 (1),2008
Number 10
Vol.10 (2), 2007
Number 10
10 (1),2007
Number 9
1&2, 2006
Number 9
3&4, 2006
Number 8
1&2, 2005
Number 8
3&4, 2004
Number 7
1&2, 2004
Number 6
3&4, 2003
Number 6
1&2, 2003
Number 5
3&4, 2002
Number 5
1&2, 2002
Number 4
Vol.3 (4), 2000
Number 4
Vol.2 (4), 1999
Number 4
Vol.1 (4), 1998
Number 4
3&4, 2001
Number 4
1&2, 2001
Number 3
Vol.3 (3), 2000
Number 3
Vol.2 (3), 1999
Number 3
Vol.1 (3), 1998
Number 2
Vol.3(2), 2000
Number 2
Vol.1 (2), 1998
Number 2
Vol.2 (2), 1999
Number 1
Vol.3 (1), 2000
Number 1
Vol.2 (1), 1999
Number 1
Vol.1 (1), 1998

 

 


 About the journal ::: Editorial ::: Subscription ::: Information for authors ::: Contact
 Copyright © Balkan Journal of Medical Genetics 2006